Agios Pharmaceuticals: Biotech Company With Upcoming FDA Approvals and Promising Pipeline

Agios Pharmaceuticals is developing therapies for rare diseases with a focus on pyruvate kinase activators such as Pyrukynd for PK deficiency. AGIO is advancing its pipeline with mitapivate research for thalassemia and sickle cell anemia and is positioning for potential FDA approvals in 2025 and 2026. Potential FDA approvals could significantly increase AGIO's revenues. Agios Pharmaceuticals (NASDAQ: AGIO) is a biotechnology company at the forefront of developing therapies for rare diseases. The company's flagship drug, Pyrukynd (mitapivate),...